Celsion Co. (NASDAQ:CLSN)’s share price gapped up before the market opened on Friday . The stock had previously closed at $2.36, but opened at $2.72. Celsion shares last traded at $2.78, with a volume of 2916000 shares changing hands.
Several research firms have recently weighed in on CLSN. Zacks Investment Research raised Celsion from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. ValuEngine raised Celsion from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th. Oppenheimer began coverage on Celsion in a research report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 target price on the stock. Finally, Maxim Group raised Celsion from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $11.90.
The company has a market cap of $44.71, a PE ratio of -0.47 and a beta of 1.22.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.